Special Edition: What's Next—Cortisol, Metabolism & Future Innovation, Part 4

Is hypercortisolism the hidden culprit in a significant proportion of both difficult-to-treat diabetes and resistant hypertension? In part 4 of our special series, Dr. Neil Skolnik speaks with John Buse, MD to explore the effects of hypercortisolism, until just recently considered a vanishingly rare condition. This special episode is sponsored with support from Corcept. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John Buse, MD, The Verne S. Caviness Distinguished Professor and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine, a past president of medicine & science at the American Diabetes Association (ADA), and recipient of the ADA Outstanding Achievement in Clinical Diabetes Research Award Selected references: Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care April 2025 Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. Diabetes Care June 2025 MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension. HCP Live March 2026